TICAVIC 60 10.S

About

Ticagrelor is an oral antiplatelet agent belonging to the class of P2Y12 inhibitors, used to prevent thrombotic events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. It works by reversibly binding to the P2Y12 receptor on platelets, thereby preventing platelet activation and aggregation. This action is crucial in inhibiting the formation of blood clots that can lead to heart attacks or strokes. Unlike clopidogrel, ticagrelor does not require metabolic activation, resulting in a more rapid and consistent antiplatelet effect.

Its efficacy in reducing the rate of cardiovascular death, myocardial infarction, and stroke in patients with ACS or a history of MI is well-established. Ticagrelor is often used in combination with aspirin for dual antiplatelet therapy, providing robust protection against recurrent ischemic events in high-risk cardiovascular patients.

Uses

• Prevention of thrombotic events in acute coronary syndrome (ACS).
• Reduction of cardiovascular death, MI, and stroke in MI history.
• Prevention of stent thrombosis after percutaneous coronary intervention (PCI).
• Used in combination with aspirin for dual antiplatelet therapy.

Directions For Use

Take as directed by your physician, usually twice daily. Swallow tablets whole with or without food.

Benefits

• Potent and rapid antiplatelet effect.
• Reduces risk of heart attack and stroke.
• Decreases cardiovascular mortality.
• Does not require metabolic activation.
• Effective in high-risk cardiovascular patients.
• Prevents stent thrombosis.

Side Effects

• Bleeding (e.g., bruising, nosebleeds)
• Dyspnea (shortness of breath)
• Headache
• Nausea
• Diarrhea
• Dizziness
• Bradycardia (slow heart rate)
• Gout
• Increased uric acid levels
• Rash
• Abdominal pain
• Fatigue

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it may increase the risk of bleeding, a common side effect of ticagrelor.
• Pregnancy - Not recommended during pregnancy unless clearly necessary, as there is limited data on human pregnancy.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if ticagrelor or its metabolites are excreted in human milk.
• Liver - Contraindicated in patients with severe liver impairment due to increased exposure to ticagrelor. Use with caution in moderate impairment.
• Kidney - No dose adjustment is generally required for kidney impairment, but use with caution in severe renal dysfunction.
• Lung - Use with caution in patients with asthma or COPD, as dyspnea (shortness of breath) is a common side effect.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.